Roivios Receives FDA Backing for Renal Assist Device and Advances Clinical Trials for Kidney Disease Treatment

New Providence, The Bahamas, New Providence, The Bahamas, June 24th, 2026, FinanceWire

Roivios, a healthtech company focused on restoring kidney function through pressure balance optimization, announced continued advancement of its JuxtaFlow Renal Assist Device (RAD) following the receipt of FDA Breakthrough Device Designation and the initiation of patient enrollment for its GRADIENT (Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic surgery outcomes) pivotal clinical trial.

The milestone marks a significant step forward for a technology designed to address one of healthcare's most persistent challenges. Millions of patients worldwide rely on treatments that primarily manage symptoms associated with declining kidney function rather than restoring the physiological conditions required for natural filtration.

Rather than focusing on compensating for kidney decline through external interventions, Roivios has developed a technology intended to restore the pressure dynamics that support normal kidney filtration.

A New Framework for Kidney Function Restoration

The company's approach is based on a fundamental observation about kidney physiology. According to Roivios, healthy kidney function depends on maintaining precise pressure relationships that drive filtration throughout the organ. When those pressure conditions become disrupted, filtration efficiency declines, often contributing to progressive loss of kidney function.

JuxtaFlow was designed to address that underlying mechanism by applying controlled negative pressure intended to rebalance filtration dynamics within the kidney.

"What sets Roivios apart is the way we approach the problem itself," said co-founder William Erbey. "Most existing treatments for kidney disease are built around managing symptoms or working around declining function. We started from a different place by asking how the kidney actually works at a mechanical level."

The company believes this pressure-based approach could represent a meaningful shift in how kidney disease is addressed by focusing on restoring function rather than simply slowing deterioration.

FDA Breakthrough Device Designation Highlights Potential

A major milestone for the company came in April 2024 when the U.S. Food and Drug Administration granted Breakthrough Device Designation for the JuxtaFlow RAD.

The designation followed clinical study results demonstrating a 70% improvement in kidney function during treatment. FDA Breakthrough Device Designation is reserved for technologies with the potential to provide more effective treatment options for patients with serious or life-threatening conditions.

"A key milestone for Roivios has been receiving FDA Breakthrough Device Designation, which reflects both the significance of the problem and the potential of the technology," Erbey stated.

The designation also enabled progression toward larger-scale clinical evaluation through the GRADIENT pivotal trial.

GRADIENT Trial Moves Technology Into Next Evaluation Phase

In August 2025, the company officially began patient enrollment for the GRADIENT pivotal trial, a study designed to evaluate the safety and effectiveness of the JuxtaFlow RAD in cardiac surgery patients with renal insufficiency.

The trial represents an important stage in validating whether restoring pressure balance within the kidney can improve filtration performance and patient outcomes at a broader scale.

Current efforts remain focused on generating robust clinical evidence while expanding the understanding of how pressure-based interventions may support kidney function in high-risk patient populations.

The company believes healthcare innovation is increasingly moving toward solutions that work with the body's natural systems rather than overriding them through external replacement approaches.

Focused on Clinical Validation and Long-Term Impact

As development progresses, Roivios continues to prioritize scientific validation and clinical evidence generation.

"In kidney disease, there have been decades of research and incremental progress, but outcomes haven't changed dramatically," Erbey noted. "That tells you something fundamental may be missing. Our approach has been to step back and examine how the kidney actually functions and what conditions it needs to operate properly."

Leadership also emphasized that some of the most impactful healthcare innovations often emerge from simplifying complex challenges rather than adding layers of intervention.

The company sees growing opportunities at the intersection of engineering, physiology, and systems-based healthcare innovation, particularly for technologies designed to address root causes of disease progression.

Looking Ahead

With FDA Breakthrough Device Designation secured and patient enrollment underway, Roivios is focused on advancing clinical trials and validating the effectiveness of the JuxtaFlow RAD on a larger scale.

The company's long-term objective is to demonstrate that restoring the kidney's natural pressure balance can significantly improve function and contribute to a new treatment paradigm for kidney disease.

As healthcare systems continue searching for solutions that move beyond symptom management, the company is positioning itself at the forefront of function-restoration technologies aimed at addressing the underlying mechanisms of renal decline.

About Roivios

Roivios is a healthtech company focused on developing renal treatment solutions designed to restore natural kidney function through pressure balance optimization. The company is currently advancing clinical trials for its JuxtaFlow Renal Assist Device following FDA Breakthrough Device Designation and ongoing evaluation through the GRADIENT pivotal study.

Contact